Oct 18 (Reuters) – NuCana PLC: * NUCANA PRESENTS ENCOURAGING DATA ON NUC-7738 IN COMBINATION WITH PD-1 INHIBITORS USING PRIMARY PATIENT-DERIVED ORGANOIDS AND AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTES AT THE ESMO CONGRESS 2025 * NUCANA PLC – REGULATORS APPROVE STUDY EXPANSION FOR 28 MORE PATIENTS * NUCANA PLC – DATA TO DATE FROM NUTIDE:701 SHOWS FAVORABLE SAFETY AND TUMOR REDUCTION Source text: Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
The Leela Annual Golf Tournament 2026 – 4th Edition, Celebrating Community, Commitment, and the Future…
Shivam Jewels selected as DTC sightholder, expected to give fresh impetus to the diamond industry.…
Ahmedabad (Gujarat) [India], March 23: Cancer care in Ahmedabad received a significant boost with the…
Mumbai (Maharashtra) [India], March 21: In a world where music and entertainment constantly evolve, few…
Scaling Impact: Desai Foundation Celebrates Reaching 12 Million Lives Surat (Gujarat) [India], March 21: The…
New Delhi [India], March 21: India’s entrepreneurial landscape is changing rapidly. More women today are…